AdvaMed Statement on the Tax Bill

WASHINGTON - Today, AdvaMed, the Medtech Association, released the following statement from President and CEO Scott Whitaker on the impact the "One Big Beautiful Bill Act" will have on medtech innovation:

"AdvaMed thanks President Trump, Vice President Vance, Senate Republican Leader Thune, House Speaker Mike Johnson, Senate Finance Chairman Crapo, and House Ways & Means Chairman Smith for the legislation passed today that will without question create a pro-growth environment that allows America's medtech industry to maintain its global leadership position going forward.

"The U.S. medical technology industry leads the world in innovation and manufacturing, filling our hospitals and clinics with American-engineered and -manufactured technologies that improve and save lives every minute of every day. The R&D and capital investment expensing provisions, for example, will spur even greater medtech R&D from our fast-moving innovators. Expansion of QSBS will support early-stage companies trying to raise capital and hire talent, which is critical to getting groundbreaking medtech developments into the hands of doctors and their patients. The steady and competitive corporate tax rate provides much-needed certainty for our companies as they plan for the future.

"Seventy percent of the medtech used in America is made in America, and medtech jobs have grown at more than three times the average since TCJA. Supporting policies that lower the cost of doing business and opposing policies that raise the cost are essential to ensuring U.S. medtech's expanding global leadership role. We look forward to continuing our work with the President and his administration and leaders on both sides of the Capitol who understand this vital policy dynamic."